NASDAQ:ZNTL
Zentalis Pharmaceuticals Inc. Stock News
$15.76
+0.570 (+3.75%)
At Close: Mar 28, 2024
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
10:56am, Wednesday, 28'th Feb 2024
The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward tre
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 28'th Feb 2024
NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiat
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
01:01pm, Thursday, 08'th Feb 2024
Zentalis Pharmaceuticals, Inc. (ZNTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term
Zentalis Pharmaceuticals: Azenosertib Continues To Impress
02:32am, Wednesday, 07'th Feb 2024
Zentalis Pharmaceuticals is positioned to become an oncology leader with its lead drug candidate, azenosertib, showing promising results in difficult-to-treat cancers. The company's financial health i
Zentalis: Latest Market Sell-Off Looks Justified With Data Catalysts Long Way Off
10:35am, Tuesday, 14'th Nov 2023
Zentalis is a biotech company focused on developing Azenosertib, a Wee1 inhibitor, for ovarian cancer. The company has faced stock sell-offs due to mixed data from clinical trials of Azenosertib in co
Zentalis: A Buy As Small Molecule Trials Continue To Advance
09:42am, Thursday, 24'th Aug 2023
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's financials show a solid cash position and efficient allocation of
Matrix Capital Infuses $108 Million Into Zentalis Toward Promising Cancer Therapeutics
10:21pm, Thursday, 22'nd Jun 2023
Shares of Zentalis Pharmaceuticals Inc (US:ZNTL) are cooling off a bit Thursday after yesterday's 4% rise capped a five-day rally of 17.8%.
Why Shares of Zentalis Pharmaceuticals Dropped This Week
02:34pm, Friday, 02'nd Jun 2023
Zentalis is a clinical-stage biotech that is focusing on cancer therapies. The stock is up more than 29% this year.
Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatmen
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
07:01am, Wednesday, 01'st Feb 2023
NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically dif
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
07:00am, Wednesday, 31'st Aug 2022
NEW YORK and SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically dif
Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded to Buy: Here's What You Should Know
01:33pm, Friday, 26'th Aug 2022
Zentalis Pharmaceuticals, Inc. (ZNTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Zentalis Pharmaceuticals (ZNTL) Might Surprise This Earnings Season
09:47am, Wednesday, 10'th Aug 2022
Zentalis Pharmaceuticals (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pfizer Injects $25M Via Equity In Zentalis Pharma
10:19am, Wednesday, 27'th Apr 2022
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) will sell 953,834 common shares at $26.21 per share to Pfizer Inc (NYSE: PFE) for $25 million. The offering is expected to close by April 29.
Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks
11:17am, Tuesday, 19'th Apr 2022
The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among